Sepp-Lorenzino Laura
Insider CIK 1777421 · NTLA EVP, Chief Scientific Officer · TSHA Director · LXEO Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies, Inc | A Award deriv | 2026-06-01 | 2026-06-02 | 42,671 | — | $0 | 42,671 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award | 2026-06-01 | 2026-06-02 | 21,335 | — | $0 | 127,178 | SEC↗ |
| LXEO Lexeo Therapeutics, Inc. | A Award deriv | 2026-04-28 | 2026-04-30 | 50,000 | — | $0 | 50,000 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award deriv | 2025-06-02 | 2025-06-04 | 113,246 | — | $0 | 113,246 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award | 2025-06-02 | 2025-06-04 | 56,623 | — | $0 | 105,843 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2025-01-03 | 2025-01-07 | 8,966 | $12.18 | $109.2K | 77,388 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2025-01-01 | 2025-01-03 | 3,500 | — | $0 | 0 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2025-01-01 | 2025-01-03 | 3,500 | — | $0 | 86,354 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award deriv | 2024-05-29 | 2024-05-31 | 98,440 | — | $0 | 98,440 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award | 2024-05-29 | 2024-05-31 | 49,220 | — | $0 | 49,220 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2024-03-01 | 2024-03-05 | 54,794 | — | $0 | 54,794 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2024-03-01 | 2024-03-05 | 37,966 | — | $0 | 81,893 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2024-01-08 | 2024-01-10 | 1,608 | $28.66 | $46.1K | 44,594 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2024-01-08 | 2024-01-10 | 667 | $29.38 | $19.6K | 43,927 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2024-01-03 | 2024-01-05 | 5,532 | $29.46 | $163.0K | 46,202 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2024-01-01 | 2024-01-03 | 3,500 | — | $0 | 3,500 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2024-01-01 | 2024-01-03 | 3,500 | — | $0 | 51,734 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award deriv | 2023-06-22 | 2023-06-26 | 36,200 | — | $0 | 36,200 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2023-03-01 | 2023-03-03 | 42,302 | — | $0 | 42,302 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2023-03-01 | 2023-03-03 | 29,938 | — | $0 | 47,567 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2023-01-05 | 2023-01-06 | 689 | $39.10 | $26.9K | 17,629 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2023-01-05 | 2023-01-06 | 1,641 | $38.22 | $62.7K | 18,318 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2023-01-04 | 2023-01-06 | 2,508 | $37.21 | $93.3K | 19,959 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2023-01-01 | 2023-01-04 | 3,500 | — | $0 | 7,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2023-01-01 | 2023-01-04 | 3,500 | — | $0 | 22,467 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award deriv | 2022-06-17 | 2022-06-22 | 15,500 | — | $0 | 15,500 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2022-03-01 | 2022-03-03 | 13,816 | — | $0 | 13,816 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2022-03-01 | 2022-03-04 | 20,203 | — | $0 | 20,203 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2022-03-01 | 2022-03-03 | 13,816 | — | $0 | 18,631 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2022-01-01 | 2022-03-03 | 3,500 | — | $0 | 10,500 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2022-01-01 | 2022-03-03 | 3,500 | — | $0 | 5,963 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2022-01-01 | 2022-03-03 | 1,148 | $112.25 | $128.9K | 4,815 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-30 | 2021-09-01 | 27,000 | — | $0 | 82,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-30 | 2021-09-01 | 70,000 | — | $0 | 80,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 3,932 | $157.77 | $620.4K | 6,766 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 15,839 | $152.75 | $2.42M | 83,552 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 28,669 | $154.77 | $4.44M | 34,238 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 16,115 | $155.61 | $2.51M | 18,123 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 7,425 | $156.79 | $1.16M | 10,698 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-30 | 2021-09-01 | 70,000 | $14.25 | $997.5K | 99,391 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 1,515 | $158.90 | $240.7K | 5,251 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 2,653 | $159.64 | $423.5K | 2,598 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 207 | $160.47 | $33.2K | 2,391 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-30 | 2021-09-01 | 20,645 | $153.64 | $3.17M | 62,907 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-30 | 2021-09-01 | 27,000 | $13.40 | $361.8K | 29,391 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise deriv | 2021-08-04 | 2021-08-06 | 26,000 | — | $0 | 109,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-04 | 2021-08-06 | 6,814 | $136.79 | $932.1K | 20,106 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-04 | 2021-08-06 | 4,419 | $138.78 | $613.3K | 9,343 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-04 | 2021-08-06 | 2,772 | $139.85 | $387.7K | 6,571 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-04 | 2021-08-06 | 4,054 | $140.73 | $570.5K | 2,517 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-04 | 2021-08-06 | 126 | $141.63 | $17.8K | 2,391 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | M Exercise | 2021-08-04 | 2021-08-06 | 26,000 | $13.40 | $348.4K | 28,391 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-04 | 2021-08-06 | 6,344 | $137.72 | $873.7K | 13,762 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2021-08-04 | 2021-08-06 | 1,471 | $135.47 | $199.3K | 26,920 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award deriv | 2021-06-17 | 2021-06-21 | 15,500 | — | $0 | 15,500 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2021-03-03 | 2021-03-05 | 84,000 | — | $0 | 84,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2021-03-03 | 2021-03-05 | 14,000 | — | $0 | 14,000 | SEC↗ |
| TSHA Taysha Gene Therapies, Inc | A Award deriv | 2020-11-23 | 2020-11-24 | 31,000 | — | $0 | 31,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2020-03-02 | 2020-03-04 | 135,000 | — | $0 | 135,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2019-06-03 | 2019-06-04 | 150,000 | — | $0 | 150,000 | SEC↗ |